🔗 Share this article

While the US proceeds with sweeping revisions to its immunization guidelines, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by casting doubt on COVID-19 vaccines throughout the global health crisis and has focused upon potential deaths following Covid immunization in her short position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Agency leaders were set to unveil sweeping changes to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US out of step with a large portion of the international standard with insufficient data for benefit. The announcement has been postponed until the new year.

Rather than the top vaccines chief, Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to lead the office this calendar year.

A Shift at the Agency

This interim role may indicate a tighter collaboration between the drug and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon dismantling long-standing immunizations at the FDA.

Høeg has repeatedly called for halting specific pediatric immunization guidelines in the US so as to align more like the Danish model, a country with comprehensive healthcare and a number of inhabitants about the size of Wisconsin’s.

To date statements, she has persisted in emphasizing on immunizations – traditionally the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Background

Dr. Høeg has no obvious background in pharmaceutical research, regulation or management, which has been customary for past leaders of the CBER. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a large organization. She lacks background in industry regulation.”

Past directors of the center would “understand legal statutes and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that former directors who headed CBER have had.”

CDER has an immense portfolio at the agency, Woodcock stated.

“The public just focuses on the new drug program, but the generic drug division clears a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and more, and all of those must be supervised,” Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant leadership component to the job, which supervises in excess of 5,000 staff members. “It’s a huge management job, if you do it right,” the former official said.

Response and Contentious Initiatives

In response to concerns about Høeg’s qualifications and whether this selection signifies increased cooperation among FDA leaders on vaccines, a spokesperson stated that the “questions stem from inaccurate premises”.

“Her experience aligns with the functions of her position,” the spokesperson stated, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a controversial rapid medication authorization process that allegedly concerned her former heads. “By what process are these medications being picked for this voucher program? Who takes the calls?” Howard questioned. “There’s a lot of lack of transparency occurring at the FDA right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent regulations of pharmaceuticals, except for immunizations.”

Established History on Immunizations

Concerning vaccines, Høeg has a clearer, if concerning, track record, critics have noted. She released a study using non-validated volunteer-provided data to assess the incidence of heart inflammation after Covid immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Among her “policy goals” for the new federal leadership encompassed revising rules for new vaccines and discontinuing “non-essential” vaccines, she said post-election on a podcast. At the FDA, Høeg has allegedly floated the idea of excluding teenage boys from receiving Covid vaccines.

“She’s an thorough dogmatist who starts off with her preconceived notions and reverse-engineers to retrofit the science in a extremely misleading, fraudulent manner,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg became part of other skeptics, {like|